Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Pretax Margin %: -9,052.58% (As of Dec. 2025)


ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
49 GF Score
Price NT$49.15
GF Value NT$25.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Pretax Margin %?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 +8.26% 49 Pretax Margin % is -9,052.58% as of Dec. 2025. GuruFocus rates ROCO:7427 with a GF Score™ of 49/100 and a GF Value™ of NT$25.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 938 Biotechnology companies, Great Novel Therapeutics Biotech & Medicals ranks worse than 92.32% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Great Novel Therapeutics Biotech & Medicals's Pre-Tax Income for the six months ended in Dec. 2025 was NT$-52.69 Mil. Great Novel Therapeutics Biotech & Medicals's Revenue for the six months ended in Dec. 2025 was NT$0.58 Mil. Therefore, Great Novel Therapeutics Biotech & Medicals's pretax margin for the quarter that ended in Dec. 2025 was -9,052.58%.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Pretax Margin % or its related term are showing as below:

ROCO:7427' s Pretax Margin % Range Over the Past 10 Years
Min: -33948.86   Med: -6226.94   Max: -1252.36
Current: -8089.05


ROCO:7427's Pretax Margin % is ranked worse than
92.32% of 938 companies
in the Biotechnology industry
Industry Median: -89.375 vs ROCO:7427: -8089.05

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Great Novel Therapeutics Biotech & Medicals Pretax Margin % Related Terms


Great Novel Therapeutics Biotech & Medicals Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Pretax Margin % Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial -5,691.59 -10,329.44 -1,257.67 -6,226.94 -8,089.05

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28,943.18 -11,756.93 -3,710.28 -7,188.92 -9,052.58

ROCO:7427 vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Pretax Margin % falls into.


ROCO:7427
49GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Great Novel Therapeutics Biotech & Medicals's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-97.473/1.205
=-8,089.05 %

Great Novel Therapeutics Biotech & Medicals's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-52.686/0.582
=-9,052.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -9,052.58% mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Pretax Margin % of -9,052.58% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #866 out of 938 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Great Novel Therapeutics Biotech & Medicals' Pretax Margin % too high?
Great Novel Therapeutics Biotech & Medicals' current Pretax Margin % is -9,052.58%. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #866 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #866 out of 938 companies for Pretax Margin %. This places Great Novel Therapeutics Biotech & Medicals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Pretax Margin % is -9,052.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.67, compared to a current price of NT$49.15 — trading 91.5% above its estimated fair value. The current Pretax Margin % is -9,052.58%. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Pretax Margin % is -9,052.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$49.15 is trading 91.5% above its estimated GF Value™ of NT$25.67. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • Pretax Margin %: -9,052.58%
  • GF Value™: NT$25.67 vs. price of NT$49.15 (91.5% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
49GF Score

Get the complete analysis for ROCO:7427

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.15
Price
NT$25.67
GF Value